Ernesto Guccione, PhD
- PROFESSOR | Oncological Sciences
- PROFESSOR | Pharmacological Sciences
Research Topics:Cancer, Developmental Biology, Epigenetics, Post-Transcriptional Processing
During my PhD at the International Center for Genetic Engineering Biotechnology (ICGEB) I have studied the oncogenic functions of HPV E6/E7 viral proteins and the relevance of splicing in regulating E6 functions. My postdoctoral work at the European Institute of Oncology I studied the role of chromatin in defining c-MYC target site recognition. I have also identified PRMT6, a member of the Protein Arginine MethylTransferase (PRMT) family, as an important enzyme regulating transcriptional repression.
In 2008 I started my lab at A*STAR in Singapore where I was promoted to Research Director and Coordinated the program of Epigenetics and Diseases.
In 2019 I moved to the department of Oncological Sciences and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai where I am currently an Associate Professor.
My lab has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology.
Currently, we are interested in the function in development and disease of Protein MethylTrasnferases (PMTs) and in modulation of Alternative Splicing using Splice switching Antisense Oligonucleotide (AON)-based approaches.
Lab Website: Guccione Lab
Multi-Disciplinary Training AreasCancer Biology [CAB], Development Regeneration and Stem Cells [DRS]
MS, University of Bologna
PhD, International School for Advanced Studies (SISSA)/International Center for Genetic Engineering Biotechnology (ICGEB)
Post Doc, European Institute of Oncology
Post-Transcriptional Processing, Epigenetics, Developmental Biology, Cancer
The Guccione lab has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology. Currently, we are interested in the function in development and disease of Protein MethylTrasnferases (PMTs) and in modulation of Alternative Splicing using Antisense Oligonucleotide (AON)-based approaches. We use biochemistry, mouse models and next generation sequencing techniques to understand the molecular mechanisms of action of candidate PMTs or specific isoforms. The range of techniques and approaches used in the lab has allowed us to characterize the mechanism of action of specific PMTs (e.g. PRMT5 and PRMT6) or oncogenic isoforms (e.g. MDM4l/s), which are now of great interest for their clinical applications.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Guccione during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- ImmuNOA Pte. Ltd.; Prometeo Therapeutics
- Alphina Therapeutics; Prometeo Therapeutics
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- ImmuNOA Pte.Ltd
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- A*STAR; LION TCR; Prelude Therapeutics
- HYRIS; ImmuNOA Pte. Ltd.
Scientific Advisory Board:
- Prometeo Therapeutics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.